Literature DB >> 1101753

Urinary metabolites of halothane in man.

E N Cohen, J R Trudell, H N Edmunds, E Watson.   

Abstract

The urinary metabolites of halothane (2-bromo-2-chloro-1,1,1-trifluoroethane) were investigated in five individuals given trace doses (25 muCi), and in three individuals given large doses (1 mCi) of radioactively labeled 14C-halothane. The latter were donor subjects for heart transplant operations. Separation of the nonvolatile urinary metabolites of halothane was accomplished by chemical extraction, electrophoresis, ion-exchange and high-pressure liquid chromatography, and gas chromatography. Identification of the individual metabolites was by nuclear magnetic resonance and mass spectrometry. Three major metabolites were identified: trifluoroacetic acid, N-trifluoroacetyl-2-aminoethanol, and N-acetyl-S-(2-bromo-2-chloro-1,1-difluoroethyl)-L-cysteine. Smaller unidentified radioactive peaks were also found. The presence of both ethanolamide and cysteine conjugates of halothane is of concern. These urinary products imply the presence of reactive intermediates. The conjugation of such intermediates to proteins and phospholipids may give rise to the high-molecular-weight covalently bound metabolites demonstrated to be present in the liver following halothane anesthesia. Elucidation of the structures of the urinary metabolites provides information important to an understanding of halothane metabolism and its potential hepatotoxicity.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1101753     DOI: 10.1097/00000542-197510000-00004

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  20 in total

Review 1.  Halothane and liver damage.

Authors:  D Rosenak; A Halevy; R Orda
Journal:  Postgrad Med J       Date:  1989-03       Impact factor: 2.401

Review 2.  Role of bioactivation in drug-induced hypersensitivity reactions.

Authors:  Joseph P Sanderson; Dean J Naisbitt; B Kevin Park
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

3.  The effects of repeated 14C halothane exposure in mice.

Authors:  W W Stoyka; G Havasi
Journal:  Can Anaesth Soc J       Date:  1977-03

Review 4.  Halothane hepatitis: what's new?

Authors:  M J Cousins
Journal:  Drugs       Date:  1980-01       Impact factor: 9.546

5.  The effect of halothane anaesthesia on liver regeneration.

Authors:  V Pratilas; M G Pratila; J P Bramis
Journal:  Can Anaesth Soc J       Date:  1978-07

6.  Reductive metabolism of carbon tetrachloride by human cytochromes P-450 reconstituted in phospholipid vesicles: mass spectral identification of trichloromethyl radical bound to dioleoyl phosphatidylcholine.

Authors:  J R Trudell; B Bösterling; A J Trevor
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

7.  Modification of liver microsomal lipids by halothane metabolites; a multi nuclear NMR spectroscopic study.

Authors:  R Müller; A Stier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

8.  Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma.

Authors:  D E Schteingart; J E Sinsheimer; R E Counsell; G D Abrams; N McClellan; T Djanegara; J Hines; N Ruangwises; R Benitez; L L Wotring
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Excretion of trifluoroacetic acid as a metabolite of halothane in digestive juices.

Authors:  M I Mirkov; M Morio; M Kawahara; O Yuge; H Kinoshita; K Fujii
Journal:  J Anesth       Date:  1988-09-01       Impact factor: 2.078

10.  Salivary excretion of trifluoroacetic acid (TFAA) after halothane anesthesia.

Authors:  M Kawahara; S Akita; T Takeshita; K Fujii; M Morio
Journal:  J Anesth       Date:  1988-09-01       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.